Global Liquid Embolics Market Size By Type (Isobutyl-2-Cyanoacrylate(IBCA), Ethanol), By Application (Tumor and Brain Cancer, Brain Arteriovenous Malformations), By Region, And Segment Forecasts, 2023...

The Global Liquid Embolics Market was valued at USD 410 million in 2023 and is projected to reach USD 1.01 billion by 2031, expanding at a CAGR of 12.0% during the forecast period (2023–2031). The market growth is driven by the increasing incidence of neurovascular disorders, advancements in embolization techniques, and rising demand for minimally invasive procedures. Liquid embolics play a vital role in the treatment of arteriovenous malformations (AVMs), aneurysms, and hypervascular tumors by obstructing abnormal blood flow. Their ability to precisely target treatment areas and reduce patient recovery time has significantly boosted adoption across neurology and oncology departments globally.

Drivers:

1. Rising Incidence of Neurovascular and Oncology Disorders:

The growing prevalence of cerebrovascular diseases such as AVMs and aneurysms is fueling demand for liquid embolic agents. Additionally, these agents are increasingly being used in the treatment of liver cancer and other hypervascular tumors, supporting their widespread adoption.

2. Advancements in Embolization Technology:

Ongoing R&D has led to the development of next-generation liquid embolics that offer improved biocompatibility, penetration, and visualization during procedures, enhancing their safety and efficacy.

3. Growing Preference for Minimally Invasive Therapies:

Liquid embolization allows for targeted, less-invasive interventions compared to open surgery, resulting in faster recovery and fewer complications, thereby gaining popularity among both patients and physicians.

Restraints:

1. High Cost of Liquid Embolic Agents and Equipment:

The elevated cost of liquid embolics and associated interventional radiology infrastructure may limit adoption, especially in low- and middle-income regions.

2. Risk of Non-Target Embolization:

Despite technological improvements, there remains a potential risk of unintentional embolization of non-target tissues, which can result in complications and limit clinician confidence in some cases.

Opportunity:

1. Expansion in Emerging Healthcare Markets:

Rapid healthcare infrastructure development in Asia-Pacific and Latin America, coupled with government initiatives to improve access to advanced treatment modalities, presents significant growth opportunities for liquid embolic vendors.

2. Integration with Image-Guided Interventions:

The increasing use of advanced imaging techniques like MRI and CT in real-time embolization enhances procedural accuracy, opening new avenues for the adoption of liquid embolics in image-guided interventions.

Market by System Type Insights:

Among the various system types, non-adhesive liquid embolics held the largest market share in 2023. These agents, such as ethylene vinyl alcohol copolymer (EVOH)-based formulations, are preferred due to their controlled delivery and reduced risk of catheter entrapment. The adhesive segment is projected to experience notable growth due to advancements in polymer formulations that improve efficacy in tumor and AVM treatments.

Market by End-use Insights:

In 2023, hospitals and specialty clinics dominated the end-use segment, driven by a growing number of embolization procedures performed in these settings and the availability of skilled interventional radiologists. The ambulatory surgical centers (ASCs) segment is expected to witness the fastest growth, owing to the trend toward outpatient treatment models and the increasing adoption of minimally invasive procedures.

Market by Regional Insights:

North America led the market in 2023, supported by the region’s advanced healthcare infrastructure, high adoption of novel interventional technologies, and strong presence of key players. Asia-Pacific is anticipated to register the highest growth rate during the forecast period, driven by rising healthcare expenditure, increasing disease awareness, and rapid expansion of interventional radiology services in countries like India and China.

Competitive Scenario:

Leading companies in the Global Liquid Embolics Market include Medtronic plc, Johnson & Johnson (CERENOVUS), Terumo Corporation, MicroVention Inc. (a Terumo Group company), Balt Extrusion, and Guerbet. These firms are investing in R&D, geographic expansion, and clinical collaborations to strengthen their portfolios and market presence.

Key Market Developments:

In 2023, Medtronic launched an updated version of its Onyx™ Liquid Embolic System with improved visibility and control for neurovascular procedures.

In 2024, Johnson & Johnson’s CERENOVUS division announced clinical trials for a next-gen polymer-based embolic agent designed for complex AVMs.

Balt Extrusion entered a strategic partnership with a leading Chinese interventional radiology group in 2025 to expand its footprint in the Asia-Pacific region.

Scope of Work – Global Liquid Embolics Market

FAQs:

1) What is the current market size of the Global Liquid Embolics Market?

The market was valued at USD 410 million in 2023.

2) What is the major growth driver of the Global Liquid Embolics Market?

The increasing incidence of neurovascular and oncology conditions requiring minimally invasive treatment options is a key growth driver.

3) Which is the largest region during the forecast period in the Global Liquid Embolics Market?

North America is expected to maintain dominance, though Asia-Pacific will exhibit the fastest growth.

4) Which segment accounted for the largest market share in the Global Liquid Embolics Market?

Non-adhesive liquid embolics held the largest market share in 2023.

5) Who are the key market players in the Global Liquid Embolics Market?

Major players include Medtronic, Johnson & Johnson (CERENOVUS), Terumo Corporation, Balt Extrusion, and Guerbet.